Go Deep
Immunic, Inc.
Immunic, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,766 | -1.7 | 0.71 | 0.00 | 632.35 |
| Oct 2026 | 21,616 | -1.9 | 0.76 | 0.00 | 674.22 |
| Oct 2026 | 21,660 | -1.8 | 0.74 | 0.00 | 660.16 |
| Oct 2026 | 19,854 | -1.8 | 0.75 | 0.00 | 662.77 |
| Oct 2026 | 19,711 | -1.9 | 0.79 | 0.00 | 702.59 |
| Oct 2026 | 19,687 | -2.0 | 0.80 | 0.00 | 707.47 |
| Oct 2026 | 19,775 | -1.9 | 0.77 | 0.00 | 681.50 |
Immunic, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -34,099,000.0 | -32,588,000.0 | -19,300,000.0 | -25,579,000.0 |
| EPS | -0.8 | -1.1 | — | -1.3 |
Immunic, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -97,172,000.0 | -100,507,000.0 | -93,612,000.0 | -120,407,000.0 | — |
| EPS | -6.2 | -10.0 | -21.1 | -37.8 | — |
Immunic, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 24,052,000.0 | 40,868,000.0 | 54,299,000.0 | 127,753,000.0 | — |
| Total Liabilities | 30,725,000.0 | 22,439,000.0 | 25,368,000.0 | 14,069,000.0 | — |
| Total Equity | -6,673,000.0 | 18,429,000.0 | 28,931,000.0 | 113,684,000.0 | — |
Owes vs Owns
Immunic, Inc. owed $0.20 for every $1 it owned in Jun 2026, up from $0.11 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.20× | 1.28× | 0.55× | 0.47× | 0.11× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Immunic, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 64.4%Receivables 17.1%Fixed assets (tangible) 4.9%Other assets 13.6%
How it's funded — Dec 2025
Short-term debt 1.5%Payables 30.9%Other liabilities 67.2%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 15.5 | 35.7 | 46.7 | 116.4 |
| Receivables | 4.1 | 0.7 | 2.5 | 2.7 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 1.2 | 1.5 | 1.8 | 1.8 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 3.3 | 3.0 | 3.4 | 6.9 |
| Liabilities & equity | ||||
| Short-term debt | 0.5 | 0.7 | 0.7 | 0.6 |
| Long-term debt | 0.1 | 0.3 | 0.6 | 1.0 |
| Payables | 9.5 | 7.6 | 4.7 | 3.7 |
| Other liabilities | 20.7 | 13.9 | 19.3 | 8.8 |
| Shareholders' equity | -6.7 | 18.4 | 28.9 | 113.7 |
| Net tangible assets | -6.7 | 18.4 | 28.9 | 113.7 |
Immunic, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -85,806,000.0 | -84,766,000.0 | -70,828,000.0 | -65,144,000.0 | — |
| Investing Activities | -161,000.0 | -264,000.0 | 9,462,000.0 | -9,741,000.0 | — |
| Financing Activities | 65,577,000.0 | 74,541,000.0 | 1,033,000.0 | 95,760,000.0 | — |